Haematology Working Party
Submitted by Anonymous (not verified) on 4 February 2025 - 13:40
Haematology Working Party
Biologics Working Party
Submitted by Anonymous (not verified) on 4 February 2025 - 13:30
Biologics Working Party
Biosimilar Medicinal Products Working Party
Submitted by Anonymous (not verified) on 4 February 2025 - 13:30
Biosimilar Medicinal Products Working Party
Cardiovascular Working Party
Submitted by Anonymous (not verified) on 4 February 2025 - 13:30
Cardiovascular Working Party
Central Nervous System Working Party
Submitted by Anonymous (not verified) on 4 February 2025 - 13:30
Central Nervous System Working Party
Human medicines European public assessment report (EPAR): Izelvay, avacincaptad pegol, Status: Application withdrawn
Submitted by Anonymous (not verified) on 4 February 2025 - 10:53
Human medicines European public assessment report (EPAR): Izelvay, avacincaptad pegol, Status: Application withdrawn
PSUSA/00000408/202405
Submitted by Anonymous (not verified) on 3 February 2025 - 16:30
PSUSA/00000408/202405
Qualification of non-mutagenic impurities - Scientific guideline
Submitted by Anonymous (not verified) on 3 February 2025 - 15:51
Qualification of non-mutagenic impurities - Scientific guideline
Nanotechnology-based medicinal products for human use EU-IN Horizon Scanning Report
Submitted by Anonymous (not verified) on 3 February 2025 - 15:46
Nanotechnology-based medicinal products for human use EU-IN Horizon Scanning Report
Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Date of authorisation: 26/07/2018, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 3 February 2025 - 15:14
Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Date of authorisation: 26/07/2018, Revision: 13, Status: Authorised